Pharmaceutical giants Bayer Healthcare and Janssen Pharmaceuticals Inc. announced on March 25, 2019, that they would pay $775 million to settle approximately 25,000 cases, which alleged that these defendants failed to warn of the possibility of internal bleeding caused by the blood thinner Xarelto. The defendants agreed to divide the payment evenly after five intense years of litigation.
The settlement ends all claims in the multidistrict litigation in Louisiana, as well as other state courts. Per the terms of the agreement, the defendants may opt to withdraw the settlement if certain participation rates are not met.
A spokesperson for Bayer stated that the company continues to believe that the claims are without merit, and there is absolutely no admission of liability under the agreement. Further, the company said that the settlement allows it to avoid the distraction and significant cost of continuing the litigation.
The cases are In re Xarelto Litigation, case No. 150102349, in the Court of Common Pleas of Philadelphia County; and In re Xarelto (Rivaroxaban) Products Liability Litigation, case No. 2:14-md-02592, in the U.S. District Court for the Eastern District of Louisiana.